Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blais

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
The Journal of Biological Chemistry|May 6, 2010
A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivityJaime D Blais, King-Tung Chin, Ester Zito, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 27, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 6, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.
Journal of the American Society of Nephrology : JASN|December 7, 2016
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 TrialOlivier Devuyst, Arlene B Chapman, Ron T Gansevoort, et al.
Journal of Digital Imaging|May 28, 2017
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic KidneysTimothy L Kline, Panagiotis Korfiatis, Marie E Edwards, et al.
Molecular and Cellular Biology|October 13, 2006
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stressJaime D Blais, Christina L Addison, Robert Edge, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVicente E Torres, Eiji Higashihara, Olivier Devuyst, et al.
The New England Journal of Medicine|November 7, 2017
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2016
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled TrialNiek F Casteleijn, Jaime D Blais, Arlene B Chapman, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The Journal of Biological Chemistry|May 6, 2010
A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivityJaime D Blais, King-Tung Chin, Ester Zito, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 27, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 6, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.
Journal of the American Society of Nephrology : JASN|December 7, 2016
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 TrialOlivier Devuyst, Arlene B Chapman, Ron T Gansevoort, et al.
Journal of Digital Imaging|May 28, 2017
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic KidneysTimothy L Kline, Panagiotis Korfiatis, Marie E Edwards, et al.
Molecular and Cellular Biology|October 13, 2006
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stressJaime D Blais, Christina L Addison, Robert Edge, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 26, 2016
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 TrialVicente E Torres, Eiji Higashihara, Olivier Devuyst, et al.
The New England Journal of Medicine|November 7, 2017
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 19, 2016
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled TrialNiek F Casteleijn, Jaime D Blais, Arlene B Chapman, et al.
Pageof 6